 |
|
Preliminary Study of the Efficacy of Insulin Aerosol Delivered by Oral Inhalation in Diabetic Patients
Beth L. Laube, PhD;
Angeliki Georgopoulos, MD;
G. K. Adams III, PhD
JAMA. 1993;269(16):2106-2109.
Abstract
| |
Objective.
—To maximize deposition of an aerosolized dose of insulin (mean± SD=0.99±0.06 U/kg of body weight) in the lungs of subjects with non—insulin-dependent diabetes mellitus (NIDDM), and investigate its efficacy in normalizing plasma glucose levels during the fasting state.
Design.
—Nonrandomized, placebo-controlled trial.
Setting.
—A primary care facility.
Patients or Other Participants.
—Six nonobese, nonsmoking volunteers with NIDDM. No subjects withdrew from the study.
Intervention.
—Aerosolized insulin was administered by oral inhalation after a 12-hour period of fasting. Aerosol was generated by a raindrop nebulizer from regular 500 U/mL pork insulin. During inhalation, inspiratory flow was regulated at 17 L/min. Plasma samples were collected after inhalation and analyzed for insulin and glucose levels.
Main Outcome Measures.
—Plasma insulin and glucose levels.
Results.
—Deposition of the aerosol was maximized within the lungs, with 79% ±17% of the inhaled dose depositing below the larynx. Geometric mean fasting plasma insulin level was 71 pmol/L (11.8 µU/mL), rising to 269 pmol/L (44.8 µU/mL) after insulin inhalation. Average time to peak insulin level was 40±34 minutes. The mean fasting plasma glucose level (12.63±2.59 mmol/L [225.5±46.3 mg/dL]) was reduced to within the normal range in five subjects and was almost normal in the sixth subject (5.52±0.89 mmol/L [98.6±15.9 mg/dL]). Average maximum decrease in plasma glucose from baseline was 55%±10% (n=6) vs 13%±9% after placebo aerosol inhalation (n=3). No side effects were reported following insulin or placebo aerosol inhalation.
Conclusions.
—These preliminary results indicate that a dose of approximately 1.0 U of aerosolized insulin per kilogram of body weight, delivered by oral inhalation and deposited predominantly within the lungs, is well tolerated and can effectively normalize plasma glucose levels in patients with NIDDM.
(JAMA. 1993;269:2106-2109)
Author Affiliations
From The Johns Hopkins University School of Hygiene and Public Health, Division of Radiation Health Sciences (Dr Laube), and The Johns Hopkins University School of Medicine, Divisions of Endocrinology (Dr Georgopoulos) and Allergy and Clinical Immunology (Dr Adams), Baltimore, Md. Dr Georgopoulos is currently with the VA Medical Center, Minneapolis, Minn.
Footnotes
This is publication 040 from The Johns Hopkins Asthma and Allergy Center.
Reprint requests to Room 2001, Johns Hopkins University School of Hygiene and Public Health, 615 N Wolfe St, Baltimore, MD 21205 (Dr Laube).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
AIR Inhaled Insulin in Subjects With Chronic Obstructive Pulmonary Disease: Pharmacokinetics, glucodynamics, safety, and tolerability
Rave et al.
Diabetes Care 2007;30:1777-1782.
ABSTRACT
| FULL TEXT
Inhaled insulins
Ghosh and Collier
Postgrad. Med. J. 2007;83:178-181.
ABSTRACT
| FULL TEXT
Concept, Strategies, and Feasibility of Noninvasive Insulin Delivery
Cefalu
Diabetes Care 2004;27:239-246.
ABSTRACT
| FULL TEXT
Treating Diabetes With Aerosolized Insulin
Laube
Chest 2001;120
:99S-106S.
ABSTRACT
| FULL TEXT
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus
Cefalu et al.
ANN INTERN MED 2001;134:203-207.
ABSTRACT
| FULL TEXT
Inhaled Insulin for Type 2 Diabetes: Solution or Distraction?
Nathan
ANN INTERN MED 2001;134:242-244.
FULL TEXT
Toward Improved Glycemic Control in Diabetes: What's on the Horizon?
Gray and O'Rahilly
Arch Intern Med 1995;155:1137-1142.
ABSTRACT
Recent Advances: Clinical pharmacology and therapeutics
Breckenridge
BMJ 1995;310:377-380.
FULL TEXT
AEROSOLIZED INSULIN FOR DIABETES
JWatch General 1993;1993:5-5.
FULL TEXT
|
